April 2025 Utilization Management Changes

Effective April 1, 2025, there will be an enhancement in coverage of certain medications for Commercial and Healthcare Reform members.

- The medications outlined in <u>Table 1</u> may now require Step Therapy (ST), Prior Authorization (PA), or be subject to a Quantity Limit (QL).
 - o Some medications are being added to the Specialty Pharmacy Copay drug list.
 - o Some medications will no longer be covered under the prescription benefit.
 - o New Utilization Management requirements for fully insured members in New York will instead occur upon group renewal date.

UPPER CASE= brand name drug lower case= generic drug

TABLE 1 – Utilization Management Changes

Drug Name	Commercial Comprehensive	Commercial Core	Commercial National Select	HCR Comprehensive	HCR Essential
Oracea capsules doxycycline monohydrate 40mg	Adding QL (1 capsule per day)				
Ergotamine-caffeine tablets	_	IAdding QL (40 tablets per 21	• '	9	Adding PA and ST Adding QL (40 tablets per 21 days)
Bimzelx 160mg/mL	Changing QL (1 unit per 21 days)				
midazolam vials* midazolam CARPUJECT*	9	_	_	•	No longer covered under prescription benefit
desonide 0.05% lotion fluticasone prop 0.05% lotion beser 0.05% lotion clobetasol emollnt 0.05% foam clobetasol emollnt 0.05% foam tovet emollient 0.05% foam	Adding PA and ST	Adding PA and ST		Adding PA and ST	Adding PA and ST
tretinoin gel micro 0.1% tube tretinoin gel micro 0.1% pump tretinoin gel micro 0.04% tube tretinoin gel micro 0.04% pump	Adding PA and ST	Adding PA and ST		Adding PA and ST	Adding PA and ST

^{*}Medication may be covered under the medical benefit.